Magellan
Magellan is a private Australian company with expertise in research, development and manufacturing of stem cells for the treatment of osteoarthritis. We lead the way globally in scientific, clinical and commercial expertise for stem cell supply and development, for both autologous treatments which use the patient’s own cells, and allogeneic treatments which use selected donor cells. We have over ten years of stem cell commercial manufacturing expertise and have cultured more than 300 billion stem cells during this time.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
Welcome
Osteoarthritis is the leading cause of pain, disability, and early retirement in more than 100+million people in the developed world. The osteoarthritis pharmaceutical therapeutics market size was $9+ billion per annum in 2020 and projected to grow to $14+ billion per annum by 2025.
Magellan Stem Cells is at the forefront of stem cell research for osteoarthritis globally. We are leading the way in scientific, clinical and commercial expertise for stem cell supply and development, for both autologous treatments which use the patient’s own cells, and allogeneic treatments which use selected donor cells.
Osteoarthritis is globally recognised as an unmet clinical need. In Australia alone, more than 2.2 million people are suffering with osteoarthritis and $3.4 billion is spent annually on osteoarthritis treatments, with half of this on joint replacements. The economic burden to Australia in direct and indirect costs is $23.9 billion per annum and it is now a National Health Priority.
The cost of osteoarthritis is more than 1% p.a. of GDP in developed nations and is now a National Health Priority in Australia. The average non-surgical medical cost per patient is $5.9K p.a USD.
The osteoarthritis pharmaceutical therapeutics market is growing rapidly, with $7.3B spent in 2020 and projected to increase to $11B p.a. by 2025.
Additionally, the data and experience from the treatment of more than 800 autologous patients, has enabled the identification of optimum donor cells, to use in our allogeneic phase 1-3 research and treatment of osteoarthritis.
Additionally, the data and experience from the treatment of more than 1000 autologous patients, has enabled the identification of optimum donor cells, to use in our allogeneic P1/2/3 research trials for the treatment of osteoarthritis.
100M+ people in developed world and >650M globally have OA. 20% of people are over 45 years and 80% of people are over 65 years.
Treatments used today have limited short term pain improvement with no disease modification and a potential risk of significant side effects.
The cost of osteoarthritis is more than 1% p.a. of GDP in developed nations and is now a National Health Priority in Australia. The average non-surgical medical cost per patient is $5.9K p.a USD.
The osteoarthritis pharmaceutical therapeutics market is growing rapidly, with $9B spent in 2020 and projected to increase to $14B p.a. by 2025.
About us
Magellan Stem Cells is a private Australian company with expertise in research, development and manufacturing of stem cell therapies for the treatment of osteoarthritis.
We lead the way globally in scientific, clinical, and commercial expertise for stem cell supply and product development. Magellan Stem Cells value is its knowledge and experience in the efficient and low- cost culturing of stem cells. Additionally, the data and experience from the treatment of more than 1000 autologous patients, has enabled the identification of optimum donor cells, to use in our allogeneic phase 1-3 research and treatment of osteoarthritis.
Magellan Stem Cells current autologous treatments for osteoarthritis have shown in our patient clinical trials:
- Substantial pain relief
- Improvement in function and mobility
- Halting of disease progression with the potential of delay and/or possible elimination of the need for expensive joint replacement surgery.
Our vision is to improve and enrich the lives of people currently struggling with osteoarthritis across the globe, by significantly reducing pain and improving their mobility.
Our product, MAG200 will be an off-the-shelf product to reduce pain in people whose joints are affected by Osteoarthritis, potentially eliminating the need for joint replacement surgery.
Our leading peer reviewed research and development has led to a world first publication using autologous (patient’s own) stem cell therapy in the successful management of Osteoarthritis. We are now undertaking the largest registered clinical trial with adipose derived mesenchymal stem cells therapy for Osteoarthritis in the world.
- Increase in OA with ageing population
- Current treatments have poor efficacy
- High growth global market
- Significant healthcare cost to society
- Major unmet global clinical need
Magellan Stem Cells has secured a laboratory in southeast Melbourne and will shortly commence construction of a good manufacturing practice laboratory with the aim to complete by fourth quarter of 2023.
Our Vision
Our vision is to improve and enrich the lives of people currently struggling with osteoarthritis across the globe, by significantly reducing pain and improving their mobility.
Our product, MAG200 will be an off-the-shelf product to reduce pain in people whose joints are affected by Osteoarthritis, potentially eliminating the need for joint replacement surgery.
Science and Technology
There are currently 100 million people with osteoarthritis in Europe, UK, USA, Canada, Japan and Australia with over 500 million globally. About 20% of these people are over 45 years old, and 80% over 65 years old. With an ageing population as well as other health factors in the rise, these numbers will continue to rise rapidly.
Governments across the world globe are making osteoarthritis a National Health Priority as the consequences to economies, health services and work productivity are significant.
In Australia alone, at least 2.2 million people between 25-64 years old are affected with arthritis at a cost to our economy of more than $23.9 billion AUD every year in direct and indirect costs. This number is projected to increase 58% by the year 2032.
In response to this growing medical condition, the osteoarthritis therapeutics market size was greater than $7.3 billion USD per annum in 2021 and predicted to grow to $11 billion USD per annum by 2025.
Magellan’s Stem Cell Research
Medical treatment available today focuses on managing pain and symptoms, rather than treating the disease itself. These treatments have limitations, with significant side effects and only some improvement in pain using analgesics, cortisone and hyaluronic acid.
We have entered the era of regenerative medicine and Magellan is in a prime position to take a leading role.
Magellan’s stem cell research is regenerative medicine, harnessing the body’s natural restorative abilities to rebuild normal function.
Product Development Pathway
Magellan Stem Cells is a world leader in the supply of Mesenchymal Stem Cells (MSC’s) to clinicians to treat osteoarthritis. We are aiming to be first to market with a global product for the regenerative treatment of osteoarthritis .
We will begin Phase III which is the Pivotal Clinical and Efficacy study fourth quarter 2023. This phase includes the final stages of further developing and commercialising MAG200 and an opportune time for investors to join us in going to market. This phase will also include:
- 13 year R&D and clinical trial journey
- Successful P1/2 Allogeneic Trial reviewed by TGA
- Allogeneic Trial synopsis reviewed and accepted by TGA
The TGA have confirmed the study is well designed and upon a successful outcome, will be sufficient for ARTG registration in 2026.
Investment Summary
Magellan Stem Cells product MAG200 is an exciting investment opportunity for strategic investors, addressing a global and currently unmet medical need. Our 13 years of intensive research which includes pre-clinical research and Phase 1-2 trials for clinical safety and efficacy, our product MAG200 has been developed as an off-the-shelf allogeneic stem cell treatment for osteoarthritis.
In the fourth quarter of 2023, Magellan Stem Cells product MAG200 will enter a pivotal P3 clinical trial. Our trial synopsis has been reviewed and accepted by the TGA. This phase presents a prime opportunity for investors who value emerging technologies in biomedical research.
With unique proprietary information and intellectual property, supported by strong patent portfolio protection, Magellan Stem Cells product MAG200 is a scalable global treatment with the potential for significant market penetration.
Investment Opportunity
We are in strategic discussions with interested investors and offering a minority interest in Magellan Stem Cells. We are looking for significant investment to help support the P3 clinical trial.
-
There is a very large potential international market for an efficacious treatment of osteoarthritis
-
More than 100 million people have in Europe, UK, USA, Canada, Japan and Australia are suffering from osteoarthritis
-
The estimated cost of an approved product MAG200 treatment is less than 20% of the cost of joint replacement
-
Magellan Stem Cells is expecting to generate substantial and increasing revenues from 2026 onwards and is projecting a positive EBITDA in the first year of commercial sales.